Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 50.1% in April

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 181,900 shares, an increase of 50.1% from the March 31st total of 121,200 shares. Based on an average daily trading volume, of 78,700 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.3% of the shares of the stock are sold short.

Gyre Therapeutics Trading Down 4.0 %

Shares of NASDAQ GYRE traded down $0.68 during midday trading on Monday, reaching $16.43. 36,060 shares of the company were exchanged, compared to its average volume of 82,941. The company’s 50-day moving average price is $17.67. The stock has a market capitalization of $1.40 billion, a PE ratio of -0.79 and a beta of 2.11. Gyre Therapeutics has a one year low of $3.00 and a one year high of $30.40.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.